Christopher F. Barnett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher F. Barnett has a total of 450 co-authors. Here are the top co-authors by number of shared publications:
- David D. Berg
Harvard Medical School
8 shared publications - Alexander I. Papolos
MedStar Washington Hospital Center, Washington, District of Columbia, USA
7 shared publications Jacob C. Jentzer
Mayo Clinic, Rochester, Minnesota, USA
7 shared publicationsJason N. Katz
Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA
7 shared publicationsMichael A. Solomon
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA; Cardiovascular Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
7 shared publications- Samuel B. Brusca
Division of Cardiology University of California San Francisco San Francisco California USA
6 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Hyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in veno-arterial extracorporeal membrane oxygenation patients
Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.
- 4 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Open AccessHyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in veno-arterial extracorporeal membrane oxygenation patients
Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- 7 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (9) , e013778
Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN)
BACKGROUND: The paucity of data to guide selection of specific vasoactive agents in patients with cardiogenic shock (CS) may lead to variability in practice patterns. The level of variability and specific factors that are associated with the use of vasoactive medications and inodilators have not been previously described. METHODS: The CCCTN (Critical Care Cardiology Trials Network) is an international, multicenter network of cardiac intensive care units (CICUs) coordinated by the TIMI Study Group. This analysis included CICU admissions for CS from 2019 to 2023. Variation in the use of inodilator treatment (dobutamine/milrinone) was assessed with multivariable mixed-effects logistic modeling. RESULTS: A total of 3282 admissions from 37 CICUs comprised the analysis cohort. The use of vasoactive medications, including inodilator treatment, varied substantially across institutions. Patient-level variables associated with greater use of inodilators included history of heart failure (odds ratio, 1.98 [95% CI, 1.61–2.44]), biventricular failure (1.59 [95% CI, 1.27–2.00]), Society of Cardiovascular Angiography and Interventions stage D (1.34 [95% CI, 1.07–1.68]), valvular disease (1.34 [95% CI, 1.03–1.74]), and male sex (1.23 [95% CI, 1.02–1.49]). Variables associated with less inodilator use included cardiac arrest (0.33 [95% CI, 0.27–0.42]), right ventricular failure (0.50 [95% CI, 0.33–0.73]), Society of Cardiovascular Angiography and Interventions stage E (0.57 [95% CI, 0.41–0.81]), acute myocardial infarction-CS (0.71 [95% CI, 0.56–0.90]), peripheral arterial disease (0.73 [95% CI, 0.54–0.99]), older age (0.77 [95% CI, 0.72–0.83], per 10-year increase), and estimated glomerular filtration rate (0.96 [95% CI, 0.93–0.99], per 10 mL/min per 1.73 m 2 increase). No individual measurable institution-level factors (eg, transplant center) were associated with variability in inodilator use. In mixed-effects logistic modeling, 45.7% of variation in inodilator use was attributed to patient-level factors and 22.7% to the random effect of individual CICU centers. Similarly, 35.3% of variation in the use of dobutamine versus milrinone was attributed to patient-level factors and 32.6% to the random effect of individual CICU centers. CONCLUSIONS: There is significant variation in vasoactive treatment and inodilator use in CS. Variation in inodilator use was associated with patient-level factors and with substantial individual CICU practice variation. Such variability underscores the need for additional high-quality evidence to guide vasoactive treatment strategies in CS.
- 7 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (9) , e013778
Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN)
BACKGROUND: The paucity of data to guide selection of specific vasoactive agents in patients with cardiogenic shock (CS) may lead to variability in practice patterns. The level of variability and specific factors that are associated with the use of vasoactive medications and inodilators have not been previously described. METHODS: The CCCTN (Critical Care Cardiology Trials Network) is an international, multicenter network of cardiac intensive care units (CICUs) coordinated by the TIMI Study Group. This analysis included CICU admissions for CS from 2019 to 2023. Variation in the use of inodilator treatment (dobutamine/milrinone) was assessed with multivariable mixed-effects logistic modeling. RESULTS: A total of 3282 admissions from 37 CICUs comprised the analysis cohort. The use of vasoactive medications, including inodilator treatment, varied substantially across institutions. Patient-level variables associated with greater use of inodilators included history of heart failure (odds ratio, 1.98 [95% CI, 1.61–2.44]), biventricular failure (1.59 [95% CI, 1.27–2.00]), Society of Cardiovascular Angiography and Interventions stage D (1.34 [95% CI, 1.07–1.68]), valvular disease (1.34 [95% CI, 1.03–1.74]), and male sex (1.23 [95% CI, 1.02–1.49]). Variables associated with less inodilator use included cardiac arrest (0.33 [95% CI, 0.27–0.42]), right ventricular failure (0.50 [95% CI, 0.33–0.73]), Society of Cardiovascular Angiography and Interventions stage E (0.57 [95% CI, 0.41–0.81]), acute myocardial infarction-CS (0.71 [95% CI, 0.56–0.90]), peripheral arterial disease (0.73 [95% CI, 0.54–0.99]), older age (0.77 [95% CI, 0.72–0.83], per 10-year increase), and estimated glomerular filtration rate (0.96 [95% CI, 0.93–0.99], per 10 mL/min per 1.73 m 2 increase). No individual measurable institution-level factors (eg, transplant center) were associated with variability in inodilator use. In mixed-effects logistic modeling, 45.7% of variation in inodilator use was attributed to patient-level factors and 22.7% to the random effect of individual CICU centers. Similarly, 35.3% of variation in the use of dobutamine versus milrinone was attributed to patient-level factors and 32.6% to the random effect of individual CICU centers. CONCLUSIONS: There is significant variation in vasoactive treatment and inodilator use in CS. Variation in inodilator use was associated with patient-level factors and with substantial individual CICU practice variation. Such variability underscores the need for additional high-quality evidence to guide vasoactive treatment strategies in CS.
- Open Access
- 25 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102629
Physician Burnout and Work Satisfaction in the Cardiac Intensive Care Unit
- 25 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102629
Open AccessPhysician Burnout and Work Satisfaction in the Cardiac Intensive Care Unit
- Open Access
Cardiovascular complications are rare in severe COVID-19 presenting with myocardial injury
Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality. Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury. Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality. Results: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO2. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality. Conclusions: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.
Open AccessCardiovascular complications are rare in severe COVID-19 presenting with myocardial injury
Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality. Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury. Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality. Results: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO2. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality. Conclusions: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.
- Open Access
- 25 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 5 (1) , 102372
Modern Cardiac ICU Care Delivery and the Role of the Cardiac ICU Cardiologist
- 25 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 5 (1) , 102372
Open AccessModern Cardiac ICU Care Delivery and the Role of the Cardiac ICU Cardiologist
- Open Access
- 20 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102355
Characteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair
- 20 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102355
Open AccessCharacteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair
- Open Access
- 1 October 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102065
Association Between Pressure-Adjusted Heart Rate and In-Hospital Mortality in Cardiogenic Shock
- 1 October 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102065
Open AccessAssociation Between Pressure-Adjusted Heart Rate and In-Hospital Mortality in Cardiogenic Shock
- Open Access
- 28 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 101816
Critical Care Cardiology
- 28 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 101816
Open AccessCritical Care Cardiology